

CORRECTION

Open Access



Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

Stephen D. Silberstein^{1*}, Virginia L. Stauffer², Katie A. Day², Sarah Lipsius³ and Maria-Carmen Wilson⁴

Correction to: J Headache Pain

<https://doi.org/10.1186/s10194-019-1024-x>

After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.

Author details

¹Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA. ²Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA. ³Syneos Health, Raleigh, NC, USA. ⁴Ochsner Health System, Covington, LA, USA.

Published online: 27 December 2019

Reference

1. Silberstein et al (2019) Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). *J Headache Pain* 20:75. <https://doi.org/10.1186/s10194-019-1024-x>

* Correspondence: stephen.silberstein@jefferson.edu

The original article can be found online at <https://doi.org/10.1186/s10194-019-1024-x>

¹Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA

Full list of author information is available at the end of the article



